Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Lifts Cloud Over J&J’s Xarelto With ROCKET-AF Re-Analysis

Executive Summary

Agency reaffirms safety and efficacy in atrial fibrillation patients despite use of faulty coagulation monitoring device in pivotal trial led by current FDA Commissioner Robert Califf when he was at Duke University.


Related Content

Bayer's Xarelto 'Safe' Despite ROCKET Device Defect
Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
J&J Saves Xarelto; But Faces tough Label
ROCKET AF’s Design Causes Headaches For Xarelto Sponsors


Related Companies